Stock listing

NASDAQ:ACRV Acrivon Therapeutics, Inc. Stock

Home listing (NASDAQ) of Acrivon Therapeutics, Inc.

Follow Acrivon Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ACRV

$1.15 USD -0.25 (-17.9%)

Close on Nov 20, 2026

Past year -49.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.971 – $1.40 USDNov 20, 2026
Volume
1.29M sharesNov 20, 2026
Market cap
$49.35M USDAt the close on Nov 20, 2026 · price × 42.91M shares outstanding
52-week range
$0.971 – $3.56 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$504,941 USDMedian day 223,250 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Acrivon Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ACRV · Home$1.15 USD-0.25 (-17.9%)1,294,096$1.40$1.40$0.971$1.40Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ACRV · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.15-0.25-17.9%$1.40$1.40$0.9711,294,096
$1.40-0.16-10.3%$1.59$1.59$1.40375,006
$1.56+0.13+9.1%$1.44$1.60$1.44612,608
$1.43-0.03-2.1%$1.45$1.56$1.39428,288
$1.46+0.01+0.7%$1.43$1.49$1.40343,021
$1.45-0.01-0.7%$1.47$1.50$1.40199,700
$1.46-0.11-7.0%$1.60$1.60$1.44334,500
$1.570.000.0%$1.57$1.65$1.55218,300
$1.57-0.01-0.6%$1.57$1.65$1.5581,200
$1.58-0.03-1.9%$1.61$1.70$1.56229,500
$1.61+0.04+2.5%$1.50$1.70$1.48364,500
$1.57-0.17-9.8%$1.73$1.73$1.51314,300
$1.74+0.07+4.2%$1.69$1.77$1.65127,900
$1.67+0.06+3.7%$1.61$1.67$1.61133,800
$1.61-0.05-3.0%$1.66$1.707$1.58228,200
$1.66-0.10-5.7%$1.74$1.76$1.65165,700
$1.76-0.03-1.7%$1.80$1.85$1.71110,500
$1.79+0.05+2.9%$1.69$1.79$1.678133,200
$1.74+0.02+1.2%$1.73$1.78$1.63168,500
$1.72-0.01-0.6%$1.74$1.77$1.69259,100
$1.73-0.03-1.7%$1.76$1.82$1.68108,200
$1.76-0.065-3.6%$1.84$1.86$1.7290,200
$1.825+0.03+1.7%$1.80$1.88$1.80159,100
$1.795+0.105+6.2%$1.78$1.82$1.75185,000
$1.69+0.05+3.0%$1.68$1.74$1.63122,200
$1.64-0.12-6.8%$1.75$1.77$1.63262,100
$1.76+0.04+2.3%$1.74$1.80$1.71114,500
$1.72-0.03-1.7%$1.73$1.81$1.70214,600
$1.75-0.15-7.9%$1.86$1.872$1.74477,200
$1.90-0.01-0.5%$1.91$1.929$1.87140,200
$1.91+0.04+2.1%$1.88$1.955$1.862192,000
$1.87-0.01-0.5%$1.89$1.905$1.78419,700
$1.88+0.02+1.1%$1.85$1.913$1.82283,500
$1.86-0.12-6.1%$2.00$2.07$1.85158,300
$1.98-0.01-0.5%$1.99$2.035$1.91402,100
$1.99-0.02-1.0%$2.05$2.06$1.99205,100
$2.01-0.04-2.0%$2.02$2.12$2.00316,900
$2.05-0.03-1.4%$2.09$2.16$2.04175,100
$2.08+0.02+1.0%$2.05$2.12$2.05132,500
$2.06-0.04-1.9%$2.08$2.12$2.025231,000
$2.10-0.02-0.9%$2.12$2.13$2.07181,900
$2.12+0.06+2.9%$2.10$2.15$2.04316,700
$2.06-0.09-4.2%$2.14$2.17$2.025433,200
$2.15+0.14+7.0%$2.04$2.24$2.01572,500
$2.01+0.16+8.6%$1.89$2.025$1.871333,900
$1.85+0.15+8.8%$1.71$1.895$1.69477,400
$1.700.000.0%$1.74$1.77$1.67463,700
$1.70-0.13-7.1%$1.85$1.90$1.695764,300
$1.83-0.13-6.6%$1.97$1.975$1.805303,700
$1.96-0.04-2.0%$1.98$1.99$1.94208,200
$2.00-0.04-2.0%$2.05$2.06$1.95461,600
$2.04+0.05+2.5%$2.03$2.06$1.96323,900
$1.99-0.11-5.2%$2.10$2.17$1.99238,800
$2.10-0.03-1.4%$2.13$2.175$2.07126,400
$2.13+0.07+3.4%$2.06$2.14$2.055184,500
$2.06-0.09-4.2%$2.15$2.15$2.045118,800
$2.15+0.08+3.9%$2.07$2.20$2.05131,100
$2.07-0.02-1.0%$2.07$2.125$2.025356,500
$2.09+0.03+1.5%$2.04$2.11$2.021160,100
$2.06-0.09-4.2%$2.16$2.19$2.05217,100
$2.15+0.07+3.4%$2.11$2.20$2.08188,300
$2.08-0.10-4.6%$2.17$2.19$2.08160,100
$2.18-0.02-0.9%$2.19$2.255$2.17242,700
$2.20-0.01-0.5%$2.19$2.225$2.06171,000
$2.21+0.01+0.5%$2.21$2.31$2.18360,800
$2.20-0.19-7.9%$2.33$2.37$2.17499,200
Ticker
NASDAQ:ACRV
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Acrivon Therapeutics, Inc. news

Acrivon Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 74 in all · newest Nov 16, 2026 · oldest 2023
Decks
18 decks · latest Nov 20, 2026

Where Acrivon Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ACRV · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ACRVBOATSUnited StatesUSD

Valuation

Price/book 0.7× against a median of 1.7×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$26.60M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
2.09

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Acrivon Therapeutics, Inc. · NASDAQ:ACRVUS$49.35M−US$26.60Mn/an/an/a0.7×n/a0.0×2.09
iBio, Inc. · NASDAQ:IBIOUS$51.45M−US$23.13Mn/a−21.5×n/a0.7×n/a0.0×2.01
Sirnaomics Ltd. · HKEX:2257US$51.13MUS$69.20Mn/an/an/an/an/an/an/a
Cinclus Pharma Holding AB · OMXSTO:CINPHAUS$51.07MUS$13.13Mn/a3.8×n/a2.6×−765.8%0.0×n/a
Aldeyra Therapeutics, Inc. · NASDAQ:ALDXUS$50.70MUS$9.72Mn/an/an/a1.4×n/a0.0×0.66
Clene Inc. · NASDAQ:CLNNUS$50.69MUS$58.31Mn/a245×n/an/an/an/a1.48
Aptamer Sciences, Inc. · KRX:291650US$49.50MUS$34.66Mn/a8.6×n/a1.6×−215.8%0.0×n/a
SYNTHAVERSE Spolka Akcyjna · GPW:SVEUS$48.68MUS$70.98Mn/a5.9×n/a1.7×−43.1%0.8×n/a
Heron Therapeutics, Inc. · NASDAQ:HRTXUS$48.04MUS$156.3Mn/a1.1×n/a9.8×−14.5%26.8×1.93
Helix BioPharma Corp. · TSX:HBPUS$47.94MUS$50.27Mn/an/an/a4.8×n/a0.3×0.36
Oncolytics Biotech Inc. · NASDAQ:ONCYUS$47.66MUS$45.23Mn/an/an/an/an/an/a1.27
Median of the othersUS$50.10MUS$47.75M4.9×1.7×−129.4%0.0×1.38

Forecasts

4 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
11.50 USD · Analysts' mean
EPS, year to Dec 2026
-1.86 · 4 analysts

Team and board

Officers

OfficerRole
Adam D. LevyChief Financial Officer
Eric DevroeChief Operating Officer
Mary-Alice MillerChief Legal Officer
Caroline WigerupVice President, Research and Business Operations
Kristina MassonCo-Founder, EVP, Business Operations, Site Head, Director
Erick GamelinChief Development Officer
Mansoor Raza MirzaChief Medical Officer
Michaela LevinChief Business Officer

Board

DirectorRole
Charles BaumDirector
Derek DiRoccoDirector
Ivana Magovčević-LiebischDirector
Kristina MassonCo-Founder, EVP, Business Operations, Site Head, Director
Michael TomsicekDirector
Peter Blume-JensenDirector
Santhosh PalaniDirector
Sharon ShachamDirector

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close−2.0%
Q2 2026Aug 12, 2026 · After close+7.6%
Q1 2026May 13, 2026 · After close0.0%
Q4 2025Mar 19, 2026+1.2%
Q3 2025Nov 13, 2025 · After close+8.2%
Q2 2025Aug 14, 2025 · After close−2.9%
Q1 2025May 14, 2025 · After close−3.5%
Q4 2024Mar 27, 2025−14.2%
Q3 2024Nov 13, 2024 · Before open−5.5%
Q2 2024Aug 13, 2024 · Before open−4.5%
All 17 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open−1.4%
Q4 2023Mar 28, 2024 · Before open+10.6%
Q3 2023Nov 9, 2023 · Before open−19.2%
Q2 2023Aug 11, 2023 · Before open+6.8%
Q1 2023May 9, 2023 · Before open+6.8%
Q4 2022Mar 28, 2023 · Before open−1.8%
Q3 2022Dec 15, 2022 · After close+4.1%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (November 2026)Technical14 slidesNov 20, 2026
Technical Presentation (November 2026)Technical30 slidesNov 10, 2026
Investor Presentation (September 2026)Investor deck50 slidesSeptember 2026
Technical Presentation (July 2026)Technical15 slidesJuly 2026
Investor Presentation (March 2026)Investor deck48 slidesMar 19, 2026
TD Cowen Healthcare Conference 2026Conference9 slidesMar 2, 2026
Corporate Update (February 2026)Corporate update13 slidesFeb 27, 2026
Corporate Update (January 2026)Corporate update31 slidesJan 8, 2026
Investor Presentation (September 2025)Investor deck57 slidesSep 5, 2025
Investor Day (March 2025)Investor day48 slidesMar 25, 2025
All 18 decks
DeckKindSlidesDate
Technical Presentation (September 2024)Technical45 slidesSep 16, 2024
Investor Day (April 2024)Investor day42 slidesApr 24, 2024
Investor Presentation (January 2024)Investor deck60 slidesJan 8, 2024
Corporate Update (November 2023)Corporate update56 slidesNov 9, 2023
Investor Presentation (September 2023)Investor deck49 slidesSep 5, 2023
Investor Day (May 2023)Investor day34 slidesMay 1, 2023
Investor Presentation (April 2023)Investor deck41 slidesApr 25, 2023
Corporate Update (March 2023)Corporate update40 slidesMar 13, 2023

Open Decks

IPO

Priced at US$12.50 a share on Nov 14, 2022.

Price
US$12.50 a share
Shares offered
7,550,000 shares of common stock
Offering size
US$94.4 million
Underwriters' option
Up to 1,132,500 more shares
Underwriters
JEFFERIES, COWEN, PIPER SANDLER · In the order on the cover
Shares delivered
On or about Nov 17, 2022

Steps

StepWhen
Draft sent to the SEC in confidenceAug 12, 2022
Filed publiclyOct 17, 2022
Amended twiceNewest Nov 8, 2022
Shares registered with an exchangeNov 7, 2022
Declared effective by the SECNov 9, 2022
Final prospectus, with the priceNov 16, 2022

Open IPO · From the cover of the final prospectus (424B4) filed Nov 16, 2022

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue000000
Cost of revenue1.36M1.01M536.0K1.09M832.0K13.0K
Gross profit-1.36M-1.01M-536.0K-1.09M-832.0K-13.0K
Research and development60.0M64.0M46.0M23.9M13.7M1.87M
Selling, general and administrative24.1M25.2M21.1M8.71M2.47M1.30M
Operating income-84.1M-89.2M-67.1M-32.7M-16.2M-3.17M
Depreciation and amortization1.36M1.01M536.0K364.0K37.0K13.0K
EBITDA-82.8M-88.2M-66.6M-32.3M-16.1M-3.15M
Interest expense1.49M59.0K
Income before tax-77.8M-80.4M-60.4M-31.2M-16.2M-5.31M
Income tax01-1.49M-199.6K-193.3K
Net income-77.9M-80.6M-60.4M-31.2M-16.2M-5.31M
Earnings per share, basic-2.02-2.38-2.74-7.56-9.32-0.41
Earnings per share, diluted-2.02-2.38-2.74-7.56-9.32

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents41.5M39.8M36.0M29.5M99.6M1.58M
Short-term investments77.1M139.7M91.4M98.2M0
Current assets120.4M181.6M129.7M132.1M100.4M1.72M
Property, plant and equipment4.89M4.47M3.48M2.09M290.0K59.0K
Total assets129.7M196.6M138.3M181.2M106.6M2.19M
Accounts payable2.28M758.0K5.05M904.0K964.0K136.0K
Current liabilities15.7M17.2M13.3M6.52M2.91M613.0K
Total debt2.71M3.65M4.64M4.96M5.63M58.0K
Total liabilities17.2M19.8M17.1M10.8M7.88M10.6M
Shareholders' equity112.5M176.8M121.2M170.5M-23.8M-8.41M
Shares outstanding31.6M31.2M22.5M21.9M1.77M12.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-63.7M-65.7M-42.6M-30.1M-14.0M-2.80M
Capital spending-1.67M-2.77M-1.29M-2.17M-238.0K-15.0K
Free cash flow-65.3M-68.4M-43.9M-32.3M-14.2M-2.82M
Cash from investing66.1M-51.8M50.7M-141.7M-238.0K-15.0K
Cash from financing-749.0K121.0M-1.55M101.7M112.2M2.89M
Share buybacks101.7M
Change in cash1.69M3.59M6.52M-70.1M98.0M71.0K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Current reportSEC
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 19, 2026Insider tradeSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
S-3 · Registration statementNov 16, 2026Offer documentSEC
8-K · Current reportNov 16, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026Current reportSEC
8-K · Current reportNov 6, 2026Current reportSEC
4 · Change in ownershipOct 26, 2026Insider tradeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipAug 27, 2026Insider tradeSEC
144 · Notice of proposed saleAug 25, 2026Other filingsSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 12, 2026Offer documentSEC
8-K · Current reportAug 12, 2026ResultsSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
4 · Change in ownershipAug 6, 2026Insider tradeSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
8-K · Current reportJun 17, 2026Management or board changeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
DEFA14A · Additional proxy materialMay 22, 2026Meeting noticeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 23, 2026Big-stake noticeSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 23, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 19, 2026Offer documentSEC
8-K · Current reportMar 19, 2026ResultsSEC
10-K · Annual reportMar 19, 2026Annual reportSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
8-K · Current reportMar 2, 2026Current reportSEC
8-K · Current reportFeb 27, 2026Current reportSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 15, 2026Insider tradeSEC
8-K · Current reportJan 8, 2026Current reportSEC
8-K · Current reportJan 8, 2026ResultsSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 21, 2025Big-stake noticeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
4 · Change in ownershipOct 21, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
8-K · Current reportSep 5, 2025Current reportSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
4 · Change in ownershipAug 5, 2025Insider tradeSEC
4 · Change in ownershipJul 21, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
8-K · Current reportJun 13, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 4, 2025Big-stake noticeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansMay 14, 2025Offer documentSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 1, 2025Big-stake noticeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
4 · Change in ownershipApr 29, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
3 · Initial statement of ownershipApr 21, 2025Insider tradeSEC
4 · Change in ownershipApr 18, 2025Insider tradeSEC
8-K · Current reportApr 7, 2025Current reportSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 3, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 28, 2025Offer documentSEC
8-K · Current reportMar 27, 2025Current reportSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 25, 2025ResultsSEC
8-K · Current reportMar 14, 2025Management or board changeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
4 · Change in ownershipOct 21, 2024Insider tradeSEC
8-K · Current reportOct 11, 2024Current reportSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
8-K · Current reportSep 16, 2024Current reportSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
8-K · Current reportAug 13, 2024ResultsSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
4 · Change in ownershipJul 19, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJul 10, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJul 10, 2024Big-stake noticeSEC

This page holds 200 of 359 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Acrivon Therapeutics, Inc.’s releases · as of Nov 10, 2026

Common shares
42,911,680
Fully diluted
42,911,680

Fully diluted

LineSharesAs of
Common shares42,911,680Nov 10, 2026

Share count over time

CountShares
Nov 10, 202642,911,680

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Ra Capital Management, L.P.12.2M28.5%US$25.1MSep 30, 2026
Sands Capital Alternatives, LLC2.29M5.3%US$4.69MSep 30, 2026
Acadian Asset Management LLC1.32M3.1%US$2.7MSep 30, 2026
Vanguard1.3M3.0%US$2.66MSep 30, 2026
Wellington888K2.1%US$1.82MSep 30, 2026
Two Sigma565K1.3%US$1.16MSep 30, 2026
Marshall Wace, LLP542K1.3%US$1.11MSep 30, 2026
Bridgeway Capital Management, LLC378K0.88%US$775KSep 30, 2026
Geode Capital297K0.69%US$609KSep 30, 2026
BlackRock227K0.53%US$465KSep 30, 2026
All 45 holders
HolderSharesOf the companyValueAs of
Gsa Capital Partners LLP209K0.49%US$429KSep 30, 2026
Citadel155K0.36%US$317KSep 30, 2026
Renaissance Technologies104K0.24%US$213KSep 30, 2026
Morgan Stanley104K0.24%US$213KSep 30, 2026
Northern Trust67,2020.16%US$138KSep 30, 2026
State Street67,1450.16%US$138KSep 30, 2026
Empowered Funds, LLC57,0360.13%US$117KSep 30, 2026
XTX Topco Ltd53,2190.12%US$109KSep 30, 2026
Dimensional46,1880.11%US$94,736Sep 30, 2026
Spark Investment Management LLC44,5000.10%US$91,225Sep 30, 2026
Bank of America33,7200.08%US$69,126Sep 30, 2026
UBS33,1130.08%US$67,882Sep 30, 2026
Hrt Financial LP30,1160.07%US$61,000Sep 30, 2026
Prelude Capital Management, LLC24,2870.06%US$49,788Sep 30, 2026
StoneX Group Inc.22,5730.05%US$43,122Sep 30, 2026
Jane Street22,2220.05%US$45,555Sep 30, 2026
Axq Capital, LP19,3900.05%US$39,750Sep 30, 2026
Quadrature Capital Ltd17,4300.04%US$35,732Sep 30, 2026
Goldman Sachs15,3030.04%US$31,371Sep 30, 2026
AAF Wealth Management, LLC10,6780.02%US$21,890Sep 30, 2026
Federated Hermes, Inc.7,9240.02%US$16,244Sep 30, 2026
Fidelity6,4840.02%US$13,292Sep 30, 2026
Barclays5,9450.01%US$12,187Sep 30, 2026
JPMorgan2,780<0.01%US$5,782Sep 30, 2026
Citigroup Inc2,715<0.01%US$5,566Sep 30, 2026
Nisa Investment Advisors, LLC584<0.01%US$1,197Sep 30, 2026
BNP Paribas537<0.01%US$1,101Sep 30, 2026
Redwood Park Advisors LLC500<0.01%US$1,025Sep 30, 2026
Russell Investments Group, Ltd.481<0.01%US$986Sep 30, 2026
Federation des caisses Desjardins du Quebec400<0.01%US$820Sep 30, 2026
Steward Partners Investment Advisory, LLC326<0.01%US$668Sep 30, 2026
SBI Securities Co., Ltd.75<0.01%US$154Sep 30, 2026
Robinhood Markets, Inc.37<0.01%US$76Sep 30, 2026
RBC35<0.01%Sep 30, 2026
Caitong International Asset Management Co., Ltd3<0.01%US$6Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund546K1.3%US$971KJun 30, 2026
Vanguard Extended Market Index Fund390K0.91%US$693KJun 30, 2026
Ultra-Small Company Fund316K0.74%US$562KJun 30, 2026
Fidelity Extended Market Index Fund111K0.26%US$178KMay 31, 2026
iShares Micro-Cap ETF73,8690.17%US$131KJun 30, 2026
Ultra-Small Company Market Fund58,0000.14%US$103KJun 30, 2026
Fidelity Series Total Market Index Fund27,6960.06%US$44,314May 31, 2026
Fidelity Total Market Index Fund24,8090.06%US$39,694May 31, 2026
Fidelity Nasdaq Composite Index Fund18,0530.04%US$28,885May 31, 2026
Vanguard Balanced Index Fund16,8920.04%US$30,068Jun 30, 2026
All 14 holders
HolderSharesOf the companyValueAs of
1290 VT Micro Cap Portfolio4,9410.01%US$8,795Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund2,500<0.01%US$4,450Jun 30, 2026
Total Stock Market Index Trust937<0.01%US$1,668Jun 30, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND115<0.01%US$173Jul 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Blume-Jensen Peter
Director, Officer: President and CEO
Sale1,276USD 1.45US$1,850Nov 17, 2026
Blume-Jensen Peter
Director, Officer: President and CEO
Sale504USD 1.45US$731Nov 17, 2026
Devroe Eric
Officer: Chief Operating Officer
Sale628USD 1.45US$911Nov 17, 2026
Gamelin Erick
Officer: Chief Development Officer
Sale416USD 1.45US$603Nov 17, 2026
Miller Mary
Officer: Chief Legal Officer
Sale193USD 1.45US$280Nov 17, 2026
Peterson Katharine
Officer: Chief Accounting Officer
Sale107USD 1.45US$155Nov 17, 2026
Miller Mary
Officer: Chief Legal Officer
Sale513USD 1.84US$944Oct 22, 2026
Miller Mary
Officer: Chief Legal Officer
Sale294USD 1.99US$585Oct 5, 2026
Blume-Jensen Peter
Director, Officer: President and CEO
Sale14,036USD 2.21US$31,020Aug 25, 2026
Masson Kristina
Director, Officer: EVP - Business Operations
Sale1,229USD 2.01US$2,470Aug 18, 2026
All 17 trades
TradeTradeSharesPriceValueDate
Masson Kristina
Director, Officer: EVP - Business Operations
Sale484USD 2.01US$973Aug 18, 2026
Devroe Eric
Officer: Chief Operating Officer
Sale604USD 2.01US$1,214Aug 18, 2026
Gamelin Erick
Officer: Chief Development Officer
Sale400USD 2.01US$804Aug 18, 2026
Miller Mary
Officer: Chief Legal Officer
Sale185USD 2.01US$372Aug 18, 2026
Peterson Katharine
Officer: Chief Accounting Officer
Sale101USD 2.01US$203Aug 18, 2026
Levy Adam D.
Officer: Chief Financial Officer
Sale1,142USD 1.57US$1,793Aug 4, 2026
Miller Mary
Officer: Chief Legal Officer
Sale573USD 1.76US$1,008Jul 21, 2026

Big stakes

StakeStakeSharesDateFiling
Ra Capital Management, L.P.28.80%12.3MApr 22, 2026Schedule 13D
Sands Capital Life Sciences Pulse Fund II, L.P.5.30%2.29MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Nov 9, 2022
Ivana Magovčević-Liebisch
Other companies: Quanterix Corporation (Director · Since at least Oct 2, 2024); Vigil Neuroscience Inc (President and CEO, Director · Since at least Jan 6, 2022); Absci Corporation (Director · Jul 21, 2021 – Jun 8, 2022 · Past); Spyre Therapeutics, Inc. (Director · Jun 8, 2021 – Jun 22, 2023 · Past)
Director · Since at least Feb 8, 2024
Derek DiRocco
Other companies: Mineralys Therapeutics, Inc. (Board Member · Since at least Nov 5, 2026); Evommune, Inc. (Board Member · Since at least Nov 4, 2026)
Director · Since at least May 18, 2026
Mansoor Raza Mirza
Other companies: Karyopharm Therapeutics Inc. (Director · Since at least May 28, 2025); Sera Prognostics, Inc. (Director · Since at least Apr 7, 2025)
Chief Medical Officer · Since at least Apr 9, 2025
Sharon Shacham
Other companies: Nasus Pharma Ltd. (Board Member · Since at least Mar 18, 2026); Karyopharm Therapeutics Inc. (Chief Scientific Officer · Sep 16, 2019 – Mar 29, 2022 · Past)
Director · Since at least Nov 9, 2022
Adam D. Levy
Other companies: Mineralys Therapeutics, Inc. (Chief Financial Officer · Since at least Feb 9, 2023)
Chief Financial Officer · Since at least Apr 1, 2025
Mary-Alice Miller
Other companies: Butterfly Network, Inc. (General Counsel & Corp Sec · Feb 12, 2021 – Mar 22, 2022 · Past)
Chief Legal Officer · Since at least Sep 26, 2023
Santhosh Palani
Other companies: Pyxis Oncology, Inc. (Director · Since at least Mar 12, 2024)
Director · Since at least Mar 4, 2024
Caroline WigerupVice President, Research and Business Operations · Since at least Nov 4, 2026
Charles BaumDirector · Since at least May 20, 2026
All 17 people
PersonSeat
Eric DevroeChief Operating Officer · Since at least Nov 9, 2022
Erick GamelinChief Development Officer · Since at least Nov 9, 2022
Katharine PetersonChief Accounting Officer · Since at least May 13, 2024
Kristina MassonEVP - Business Operations, Director · Since at least May 21, 2026
Michaela LevinChief Business Officer · Since at least Aug 31, 2026
Michael TomsicekDirector · Since at least May 20, 2026
Peter Blume-JensenDirector · Since at least Nov 9, 2022

Open People

Log in to ask 6ix AI your own questions about Acrivon Therapeutics, Inc.